CDK4/6 inhibitors in clinical trials
LET, letrozole; EXE, exemestane; TAM , tamoxifen; NSAI, non-steroidal aromatase inhibitor; FULV, fulvestrant
Palbociclib
Ribociclib
Abemaciclib
PALOMA-2
NCT01740427
+ LET (vs placebo)
Postmenopausal women,
first-line setting
(N~666)
PALOMA-4
NCT02297438
+ LET (vs placebo)
Asian postmenopausal
women, first-line setting
(N~330)
PEARL
NCT02028507
+ EXE (vs capecitabine)
Postmenopausal women,
refractory to NSAI
(N~348)
MONALEESA-2
NCT01958021
+ LET (vs placebo)
Postmenopausal women,
first-line setting
(N~650)
MONALEESA-7
NCT02278120
+ TAM/NSAI + goserelin
(vs placebo)
Premenopausal
women, (N~660)
MONALEESA-3
NCT02422615
+ FULV (vs placebo)
Postmenopausal women,
≤1 line of prior endocrine
treatment (N~660)
MONARCH-2
NCT02107703
+ FULV (vs placebo)
Postmenopausal women,
≤1 line of prior endocrine
treatment (N~630)
MONARCH-3
NCT02246621
+ NSAI (vs placebo)
Postmenopausal women,
first-line setting
(N=450)
